Keymed Biosciences Inc. (HKG:2162)
Hong Kong · Delayed Price · Currency is HKD 74.45
-0.25 (-0.33%)
Aug 19, 2025, 11:45 AM HKT
Keymed Biosciences Revenue
In the year 2024, Keymed Biosciences had annual revenue of 428.12M CNY with 20.91% growth. Keymed Biosciences had revenue of 373.44M in the half year ending December 31, 2024, with 592,665.08% growth.
Revenue
428.12M CNY
Revenue Growth
+20.91%
P/S Ratio
48.30
Revenue / Employee
340.32K CNY
Employees
1,258
Market Cap
22.01B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 428.12M | 74.03M | 20.91% |
| Dec 31, 2023 | 354.10M | 254.03M | 253.87% |
| Dec 31, 2022 | 100.06M | -10.21M | -9.26% |
| Dec 31, 2021 | 110.27M | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BeOne Medicines | 35.81B |
| Hansoh Pharmaceutical Group Company | 13.05B |
| JD Health International | 71.34B |
| Innovent Biologics | 10.03B |
| Akeso | 2.26B |
| Sino Biopharmaceutical | 30.72B |
| WuXi Biologics | 19.87B |
| CSPC Pharmaceutical Group | 28.99B |